MATVAX-RSV: Long term immunogenicity of maternal RSV vaccine given during pregnancy

STUDY BASICS

Are you a woman 18-49? Do you have direct exposure to at least 1 child, 3 years of age or younger for 3 or more days per week? You may be eligible for a research study that compares the antibody levels (cells that fight infection) in the blood of women who received the RSV (respiratory syncytial virus) vaccine during pregnancy to women who have not received it over time. Compensation provided.

STUDY PURPOSE

This research aims to describe how long women who are vaccinated with RSV during pregnancy have protective antibodies in their own blood. This will help us to understand how long those antibodies last and what is the likelihood that a future infant will receive enough antibodies from their mother to protect them against RSV. We will also look to see whether vaccinated women get RSV infections after they have been vaccinated and what happens to their antibodies if that happens.

COULD THIS STUDY BE RIGHT FOR YOU?

• females 18-49 years old
• have direct exposure to at least 1 child, 3 years of age or younger for 3 or more days per week

WHAT PARTICIPANTS CAN EXPECT

The study requires 4 in-person visits over the course of a year  – all at the Oakland Primary Care Clinic (across the street from Magee Hospital). They would collect blood and some medical history information from you at each of those visits. If you become pregnant and deliver during the study, there would be an additional delivery visit where they collect your blood and cord blood from the baby.